Activity Summary:
Stroke prevention continues to challenge clinicians, especially when balancing effective anticoagulation with the risks of bleeding. During this live, interactive webcast, Dr. Gibson and Dr. Patel will explore novel therapeutic approaches, including the emerging role of Factor XIa inhibition. Through the expert-led discussions, real-world case scenarios, and the latest clinical data, participants will gain new perspectives on how to reduce residual stroke risk while improving safety profiles for high-risk patients.

Activity Summary:
The introduction of kinase inhibitors has significantly impacted the treatment landscape of plexiform neurofibromas (PN) associated with neurofibromatosis type 1 (NF1). In this podcast activity from the 2025 Annual Oncology Meeting, noteworthy data in NF1-PN has been summarized and evaluated by Dr. Amy Armstrong. This activity is AMA/ABS/ANCC/ACPE accredited for one-year.

Activity Summary:
The introduction of kinase inhibitors has significantly impacted the treatment landscape of plexiform neurofibromas (PN) associated with neurofibromatosis type 1 (NF1). In this Clinical Clip activity from the 2025 Annual Oncology Meeting, noteworthy data in NF1-PN has been summarized and evaluated by Dr. Amy Armstrong. This activity is AMA/ABS/ANCC/ACPE accredited for one-year.

Activity Summary:
During this educational podcast, Dr. Sonali Bose highlights the latest advances in COPD presented at the American Thoracic Society (ATS) International Conference in San Francisco, CA, May 17-21, 2025.

Noteworthy presentations, posters, and abstracts are presented from the conference that are of high clinical significance to improve COPD.

Activity Summary:
Chronic Obstructive Pulmonary Disease (COPD) remains a major global health burden with significant gaps in early diagnosis, personalized treatment, exacerbation prevention, and coordinated care. During this Clinical Clip video, Dr. Sonali Bose highlights the latest advances in COPD presented at the American Thoracic Society (ATS) International Conference in San Francisco, CA, May 17-21, 2025.

Activity Summary:
There continues to be significant progress in the treatment of primary biliary cholangitis (PBC) and these Clinical Clips from EASL 2025 have focused on the most impactful data presented at this conference. Dr. Nancy Reau will summarize key advances from EASL 2025 and describe their implications for clinical practice. 

Activity Summary:
There continues to be significant progress in the treatment of primary biliary cholangitis (PBC) and these Clinical Clips from EASL 2025 have focused on the most impactful data presented at this conference. Dr. Nancy Reau will summarize key advances from EASL 2025 and describe their implications for clinical practice. 

Activity Summary:
In this podcast titled "Emerging Evidence in Myasthenia Gravis: Key Updates from AAN 2025," Dr. Nicholas Silvestri provides healthcare professionals with an actionable update on recent advancements in MG; which features insights from groundbreaking research presented at AAN 2025.

Activity Summary:
Myasthenia Gravis (MG) has had significant advances, however critical gaps persist in optimizing care. Challenges include variability in diagnostic accuracy, particularly in seronegative cases, and a limited adoption of newer, more sensitive testing modalities. Additionally, the evolving treatment landscape—with emerging therapies such as complement inhibitors and FcRn antagonists—highlights the need for clinicians to stay informed about the latest evidence and integrate these options into personalized care strategies. Addressing these gaps is crucial to improving patient care, enhancing quality of life, and reducing the burden of long-term side effects associated with traditional treatments.

This special edition podcast series with Dr. Nicholas Silvestri enables healthcare providers to engage with evidence-based insights and practical guidance on MG management at their convenience. The podcast format is ideal for professionals to access while commuting, during breaks, or between patient appointments, providing targeted learning without disrupting their workflow.

Activity Summary:
In this Clinical Clip, Dr. Nicholas Silvestri provides a concise and clinically relevant summary of the most important emerging data presented at AAN 2025 that impact the management of generalized Myasthenia Gravis (gMG).

Topics covered include pivotal updates from recent clinical trials—such as MINT (inebilizumab), ADAPT NXT (efgartigimod), and MycarinG (rozanolixizumab)—highlighting the safety, efficacy, and practical implications of emerging therapies across diverse MG subtypes. The activity also explores trends in real-world treatment patterns, therapeutic inertia among neurologists, and new diagnostic approaches including advanced serologic testing and AI-supported electrophysiologic tools. With a focus on individualized care, this activity equips healthcare professionals with key insights to help integrate new therapies and diagnostic innovations into practice, ultimately supporting timely, targeted, and patient-centered management of MG.

Activity Summary:
We are pleased to have recently held the Optimal Management of HIV Disease & Hepatitis: Clinical Conference XXXIII (OPMAN). The conference took place March 22-23, 2025, in Washington, D.C. with leading clinicians and researchers presenting an array of topics covering HIV disease and liver disease. The presentations offered a unique distillation of clinically focused data tailored for practicing HIV and hepatitis healthcare professionals.

These accredited video archives of OPMAN XXXIII provide access to each day of the conference, including clinical presentations, interactive case discussions, and panel discussions addressing audience questions. Continuing education credit is provided for each segment, so you may participate in your area(s) of interest. We hope you enjoy this activity!